Targeted therapy and immunotherapy are currently the main treatment methods for GC, such as HER2-targeted drugs, VEGF inhibitors, and PD-1/PD-L1 inhibitors, but drug resistance and side effects are still difficult problems in the clinical treatment of GC. Here, ERBB2 is linked to gastric cancer.